Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Shares Issued (2016 - 2025)

Viking Therapeutics' Shares Issued history spans 11 years, with the latest figure at $1.2 million for Q4 2025.

  • For Q4 2025, Shares Issued rose 17.57% year-over-year to $1.2 million; the TTM value through Dec 2025 reached $2.5 million, down 76.96%, while the annual FY2025 figure was $2.5 million, 76.96% down from the prior year.
  • Shares Issued for Q4 2025 was $1.2 million at Viking Therapeutics, up from $444000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $5.7 million in Q1 2021 and bottomed at $5000.0 in Q3 2021.
  • The 5-year median for Shares Issued is $813500.0 (2022), against an average of $1.6 million.
  • The largest YoY upside for Shares Issued was 3440.0% in 2021 against a maximum downside of 97.57% in 2021.
  • A 5-year view of Shares Issued shows it stood at $66000.0 in 2021, then skyrocketed by 127.27% to $150000.0 in 2022, then rose by 12.0% to $168000.0 in 2023, then skyrocketed by 502.98% to $1.0 million in 2024, then grew by 17.57% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for VKTX's Shares Issued are $1.2 million (Q4 2025), $444000.0 (Q3 2025), and $507000.0 (Q2 2025).